Implementing preexposure prophylaxis among key populations: an opportunity for patient-centered services and management of hepatitis B

Implementing preexposure prophylaxis among key populations: an opportunity for patient-centered services and management of hepatitis B
of 2
All materials on our website are shared by users. If you have any questions about copyright issues, please report us to resolve them. We are always happy to assist you.
  D ownl    o a d  e d f   r   omh  t    t     p s :   /    /     j    o ur  n al    s .l   ww. c  om /    ai    d  s  onl   i   n e b   y B h DMf    5  eP HK  av 1 z E  o um1  t    Qf   N4  a+ k   J  L h E Z   g b  s I   H o4 X Mi    0 h  C   y w C X 1 A WnY  Q  p /   I   l    Qr  HD 3 I    J  r   t   B K  u S  s  QV MH 9  QN2  b P  QP L 1  G S  S  u o Qf   l    oDZ  5 k   6 f    aw U1 w= on 0 4  /   2  6  /   2  0 1  8  Correspondence  AIDS  2018,  32 : 829–833 Implementing preexposure prophylaxis among key populations: an opportunity for patient-centered servicesand management of hepatitis B When taken properly, Tenofovir-based oral preexposureprophylaxis(PrEP)hasbeenproventobeefficienttopreventHIVacquisition [1–5]. Since 2015, PrEP is recommendedbytheWHOfor populationsat‘substantialrisk’ofHIV[6].However,WHOpointsouttheneedforadditionalresearchon PrEP in ‘real life’ on questions such as demand creationfororal PrEP; best delivery models indifferent contexts andfor different populations; social and behavioral impact of PrEP;orintegrationofPrEPserviceswithotherservices[6].Transitioningfromefficacytrialstoimplementationrequiresto adapt interventions. Preliminary research (ANRS 12361PrEP-CI [7]) has been conducted in Coˆte d’Ivoire (CI) incollaboration with community non-governmental orga-nizations to explore relevance and feasibilityof implement-ing a PrEP program among female sex workers, one of themost exposed populations countrywide (estimated HIVprevalence: 29% [8]). The following observations emergedfrom that collective work.AllefficacyPrEPtrialsprovidedarangeofsexualhealthcareservices in addition to PrEP drugs [9–11]. Such servicesappeared essential for any PrEP program. By design, theywere conditionaltoPrEPuse. However,regardless oftheir interest in using PrEP, female sex workers interviewed inCoˆte d’Ivoire, and more broadly key populationsworldwide [12–16], have many unmet sexual andreproductive health needs: sexually transmitted infectionsscreening and care, contraception and birth control,menstrual management, addictions and risky behaviors . . . When transitioning to real life, we should not reproducethe service model of efficacy PrEP trials, that is a PrEPprogram with additional services. Instead, a paradigm shifttoward a patient-centered approach should be preferred,that is offering sexual and reproductive health services inwhich PrEP is an option but not mandatory.In Western and Central Africa, the prevalence of hepatitisB is relatively high [17]. In Cote d’Ivoire, more than 11%of new blood donors were positive for hepatitis B surfaceantigen in 2008–2012 [18]. Tenofovir is also used for hepatitis B treatment. But, currently, treatment is not freefor monoinfected hepatitis B patients, whereas it iscovered by AIDS programs for HIV-hepatitis B coin-fected patients. In such context, it would be ethicallyunacceptable to provide free HIV PrEP without takinginto account patients in needs of hepatitis B treatment.Actually,for thosepatients,offeringTenofovir-basedHIVPrEP constitutes an opportunity to simultaneously treattheir hepatitis B. It requires to integrate WHOrecommendations on hepatitis B [19] within PrEPguidelines [20], possibly to simplify hepatitis B carealgorithms and to allow hepatitis B care in decentralizedsexual health clinics and not only in hospital services.Most efficacy PrEP trials excluded hepatitis B patients.Additional clinical research exploring interactionsbetween HIV PrEP and hepatitis B treatment, inparticular the risk of flare if PrEP is stopped, is required.PrEP programs could be built on the existing communityservices for HIVcare and treatment.Providingservicesfor HIV positives and HIV negatives within the same clinicscould be a way of minimizing the stigma associated withentry and retention into HIV care. In addition, HIVpatients have unmet sexual and reproductive health needsaswell.IntegratingservicestogetherandtransformingHIVclinics into sexual health clinics could lead to many healthoutcomes improvements and also to possible cost sharingand savings.So far, the focus of HIV programs has mainly been onreaching individuals never tested for HIV, identifying newpositives and linking them to HIV care and treatment.Transitioning PrEP from trials to implementation con-stitutes an opportunity for developing people-centeredapproaches integrating all sexual and reproductive healthservicestogether,includinghepatitisB.Itiscrucialtoavoida silo-based perspective in which services are separatedfrom each other. Moving from HIV care clinics to sexualhealthclinicswouldallowtogloballyimprovethehealthof key populations and their partners, beyond HIVoutcomesalone. To ensure the success of new prevention programs,we have to take the next step forward. Beyond biomedicalinnovations, innovations in terms of intervention imple-mentation, delivery models and public health policies areurgentlyrequired[21],inparticularinWesternandCentralAfrica [22]. Scaling-up PrEP is a key moment. We shouldnot miss out on this opportunity. Acknowledgements The PrEP-CI ANRS 12361 was funded by the Bill andMelinda Gates Foundation and the French NationalAgency for AIDS and Viral Hepatitis Research (ANRS).Author contributions: J.L. and V.B. wrote the article. Allauthors contributed to the interpretation, reviewed thearticle and approved the final version of the article. Conflicts of interest There are no conflicts of interest. ISSN 0269-9370 Copyright  Q  2018 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under theCreative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided thesrcinal work is properly cited.  829   Joseph Larmarange a  , Valentine Becquet  a  , Jean-MarieMasumbuko b  , Marcellin Nouaman b  , M   elanie Plazy  c   ,Christine Danel  b and Serge Eholi   e b  ,  a Centre Popula-tion et D  eveloppement, Institut de Recherche pour leD  eveloppement, Universit   e Paris Descartes, Inserm,Paris, France,  b Programme PAC-CI, Abidjan, Coˆ ted’Ivoire, and   c Bordeaux Population Health ResearchCenter UMR 1219, ISPED, Universit   e de Bordeaux,Inserm, Bordeaux, France.Correspondence to Joseph Larmarange, PhD, CentrePopulation et D  eveloppement, Universit   e Paris Des-cartes, 45 rue des Saints-Pe` res, 75006 Paris, France.E-mail: Received: 22 December 2017; accepted: 5 January 2018. References 1. Molina J-M, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al  .  On-demand preexposure prophylaxis in men at high riskfor HIV-1 infection.  N Engl J Med   2015;  373 :2237–2246 . 2. McCormack S,DunnDT,DesaiM, DollingDI, GafosM, GilsonR,  et al  .  Preexposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilotphaseofapragmaticopen-labelrandomisedtrial. Lancet  2016; 387 :53–60 . 3. GrantRM,LamaJR,AndersonPL,McMahanV,LiuAY,VargasL, etal  . PreexposurechemoprophylaxisforHIVpreventioninmenwho have sex with men.  N Engl J Med   2010;  363 :2587–2599 . 4. BaetenJM,DonnellD,NdaseP,MugoNR,CampbellJD,Wangisi J,  et al  .  Antiretroviral prophylaxis for HIV prevention in hetero-sexual men and women.  N Engl J Med   2012;  367 :399–410 . 5. Choopanya K, Martin M, Suntharasamai P, Sangkum U, MockPA, Leethochawalit M,  et al  .  Antiretroviral prophylaxis for HIVinfection in injecting drug users in Bangkok, Thailand (theBangkok Tenofovir Study): a randomised, double-blind, place-bo-controlled phase 3 trial.  Lancet   2013;  381 :2083–2090 . 6. Department of HIV/AIDS, World Health Organization.  Guide-line on when to start antiretroviral therapy and on preexposure prophylaxis for HIV. 2015, NBK327115/ . [Accessed 23 October 2017] . 7. Becquet V, Nouaman M, Masumbuko J-M, Anoma C, Soh K,Alain T, et al. The challenges of implementing PrEP: the case of femalesexworkersinCoˆted’Ivoire.Presentedatthe19thICASAInternational Conference on AIDS and STIs in Africa, 2017.Abidjan: Poster no. WEPDC159.8. UNAIDS.  On the fast-track to end AIDS by 2030: focus onlocation and population. 2015, . 9. Grant RM, Anderson PL, McMahan V, Liu A, Amico KR,Mehrotra M,  et al  .  Uptake of preexposure prophylaxis, sexualpractices, and HIV incidence in men and transgender womenwhohavesex with men: acohortstudy.  LancetInfectDis  2014; 14 :820–829 . 10. MolinaJ-M,CharreauI,SpireB,CotteL,ChasJ,CapitantC, etal  . Efficacy, safety, and effect on sexual behaviour of on-demandpreexposure prophylaxis for HIV in men who have sexwith men: an observational cohort study.  Lancet HIV   2017; 4 :e402–e410 . 11. Durand-Zaleski I, Mutuon P, Charreau I, Tremblay C, Rojas-Castro D, Pialoux G,  et al  .  Costs and benefits of on-demandHIV pre-exposure prophylaxis in men who have sex with menanalysis of the ANRS IPERGAY study with a one-year follow-up.  AIDS  2018;  32 :95–102 . 12. Bamba A, Grover E, Ezouatchi R, Thiam-Niangoin M, Pap-worth E, Grosso A,  et al  .   Etude biologique et comportementaledes IST/VIH/Sida chez les professionnelles du sexe du District d’Abidjan et examen des interventions en direction des popu-lations cl   es en Coˆ te d’Ivoire.  Abidjan: Ministe`re de la Sant  e etde la Lutte contre le Sida, Enda Sant  e, Johns Hopkins Uni-versity; 2014 . 13. Schwartz S, Papworth E, Thiam-Niangoin M, Abo K, Drame F,DioufD, etal  . Anurgentneedforintegrationoffamilyplanningservices into HIV care: the high burden of unplanned preg-nancy, termination of pregnancy, and limited contraceptionuse among female sex workers in Coˆte d’Ivoire.  J Acquir Immune Defic Syndr   2015;  68 :S91–S98 . 14. Katz KR, McDowell M, Green M, Jahan S, Johnson L, Chen M. Understanding the broader sexual and reproductive healthneedsoffemalesexworkersinDhaka,Bangladesh. IntPerspect Sex Reprod Health  2015;  41 :182–190 . 15. Wahed T, Alam A, Sultana S, Rahman M, Alam N, Martens M, etal  . Barrierstosexualandreproductivehealthcareservicesasexperienced by female sex workers and service providers inDhaka city, Bangladesh.  PLoS One  2017;  12 :e0182249 . 16. Ippoliti NB, Nanda G, Wilcher R.  Meeting the reproductivehealthneeds offemalekeypopulationsaffectedby HIVinlow-and middle-income countries: a review of the evidence.  Stud Fam Plann  2017;  48 :121–151 . 17. Stasi C, Silvestri C, Voller F.  Emerging trends in epidemiologyof hepatitis B virus infection.  J Clin Transl Hepatol   2017;  5 :272–276 . 18. S  eri B.  Pr   evalence, incidence et facteurs associ   es des infections par les virus du VIH, de l’h  epatite B et de l’h  epatite C chez lesdonneurs de sang: analyse de la base de donn  ees du CentreNational de Transfusion Sanguine (CNTS) d’Abidjan, 1992– 2012.  Abidjan: CNTS; 2013 . 19. World Health Organization, Global Hepatitis Programme. WHO guidelines on hepatitis B and C testing.  2017, http:// . [Accessed 24 October 2017] . 20. World Health Organization.  WHO implementation tool for  preexposure prophylaxis (PrEP) of HIV infection. World HealthOrganization; 2017 . 21. Ridde V, Olivier de Sardan JP.  La mise en œuvre des interven-tions de sant  e publique en Afrique: un the`me strat  egiquen  eglig  e [The implementation of public health interventionsin Africa: a neglected strategic theme].  M  edecine Sant   e Trop 2017;  27 :6–9 . 22. Larmarange J, Sow K, Broqua C, Akinde`s F, Bekelynck A, Kon  eM.  Social and implementation research for ending AIDS inAfrica.  Lancet Public Health  2017;  2 :e540 . DOI:10.1097/QAD.0000000000001749 John Cunningham virus large T antigen detection in brain biopsy of an HIV-infected patient withglioblastoma multiforme: more than a coincidental finding Double-stranded DNA of John Cunningham virus (JCV)contains the early genes region, the late genes region, andthe noncoding regulatory region. The large T antigen(LT-Ag), small Tantigen, and T proteins encoded by thefirst region play a critical role in the transformation,genetic regulation, and replication of the virus. The lategenes region produces the capsid proteins VP1, VP2, andVP3 in addition to the accessory Agno protein [1,2]. 830 AIDS  2018, Vol 32 No 6
Related Search
We Need Your Support
Thank you for visiting our website and your interest in our free products and services. We are nonprofit website to share and download documents. To the running of this website, we need your help to support us.

Thanks to everyone for your continued support.

No, Thanks